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Neovessel	formation	is	a	complex	process	governed	by	the	orchestrated	action	of	multiple	factors	that	
regulate	EC	specification	and	dynamics	within	a	growing	vascular	tree.	These	factors	have	been	widely	
exploited	to	develop	therapies	for	angiogenesis-related	diseases	such	as	diabetic	retinopathy	and	tumor	
growth	and	metastasis.	WNT	signaling	has	been	implicated	in	the	regulation	and	development	of	the	
vascular	system,	but	the	detailed	mechanism	of	this	process	remains	unclear.	Here,	we	report	that	Dick-
kopf1	(DKK1)	and	Dickkopf2	(DKK2),	originally	known	as	WNT	antagonists,	play	opposite	functional	
roles	in	regulating	angiogenesis.	DKK2	induced	during	EC	morphogenesis	promoted	angiogenesis	in	
cultured	human	endothelial	cells	and	in	in	vivo	assays	using	mice.	Its	structural	homolog,	DKK1,	sup-
pressed	angiogenesis	and	was	repressed	upon	induction	of	morphogenesis.	Importantly,	local	injec-
tion	of	DKK2	protein	significantly	improved	tissue	repair,	with	enhanced	neovascularization	in	animal	
models	of	both	hind	limb	ischemia	and	myocardial	infarction.	We	further	showed	that	DKK2	stimu-
lated	filopodial	dynamics	and	angiogenic	sprouting	of	ECs	via	a	signaling	cascade	involving	LRP6-
mediated	APC/Asef2/Cdc42	activation.	Thus,	our	findings	demonstrate	the	distinct	functions	of	DKK1	
and	DKK2	in	controlling	angiogenesis	and	suggest	that	DKK2	may	be	a	viable	therapeutic	target	in	the	
treatment	of	ischemic	vascular	diseases.
Introduction
Angiogenesis, the formation of new blood vessels from a preexist-
ing vascular bed, is essential for embryonic development as well as 
many pathophysiological processes in adult life, including wound 
healing, diabetic retinopathy, tumor growth, and metastasis (1–3). 
During angiogenesis, specialized ECs located at the vascular front 
undergo dynamic and coordinated phenotypic alterations in mor-
phology, cell-to-cell (and/or cell-to-matrix) communication, and 
proliferation (4–6). These cellular changes are accompanied by 
the concomitant dynamic regulation of specific gene expression 
within a developing vessel, which is indispensable for establishing 
a functional vascular network (4, 5).
Numerous studies have identified many genes with localized 
expression at the vascular front and delineated their specific func-
tions in regulating EC sprouting and remodeling during develop-
ment of the vascular tree (4, 5). VEGF, the most well-characterized 
angiogenic molecule, has been shown to guide endothelial tip cell 
filopodia via VEGFR2 at the sprouting front (2, 7). Receptors of 
neuronal axon guidance cues such as Unc5b, EphB4, Plexin D1, 
and Robo4 are also prominently expressed at the vascular front 
and play significant roles in vessel path finding and sprouting 
(8–10). Recently, Notch signaling has been shown to be a key 
player in vascular morphogenesis, particularly in confining tip 
cell and stalk cell characters, in addition to arterial-venous deter-
mination (5). Notch1 binding by Delta-like 4 (Dll4) suppresses 
tip cell formation (11–13), and blockade of Dll4-Notch1 signal-
ing in mice inhibits tumor growth by increasing the formation of 
nonproductive vessels with excessive sprouting and many small 
vessel branches (14, 15). Benedito et al. further showed that Jag-
ged1 (Jag1) antagonizes Dll4-Notch signaling in ECs expressing 
Fringe family glycosyltransferases and promotes angiogenesis 
in mice (16). The identification and characterization of factors 
regulating EC type specification and dynamics should be valu-
able for further understanding of the molecular mechanisms of 
neovascularization and for establishing new strategies for treat-
ing angiogenesis-dependent diseases.
WNT pathways have been widely implicated in regulating the 
development and maintenance of the vascular system (17). A large 
number of studies have demonstrated diverse roles of WNT signal-
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ing in regulating EC functionalities such as proliferation, survival, 
differentiation, cell junctions, and polarity (18). Indeed, genetic 
studies have demonstrated that WNT 7b induces hyaloid vessel 
regression (19) and Norrin-Frizzled4 signaling plays a key role in 
the vascular development of the eye and ear (20, 21). WNT signals 
are also considered to be orchestrated with other pathways, includ-
ing Notch and TGF-β, to regulate vascular morphogenesis (18). 
However, the function of WNTs and the underlying regulatory 
pathways in the vasculature remain unclear due to the complexity 
in spatial expression and interaction of large number of WNTs and 
their regulatory proteins.
In the present study, we observed that Dickkopf1 (DKK1) and 
DKK2, originally known as WNT antagonists that bind to LDL 
receptor–related protein (LRP) 5/6 and inhibit β-catenin signaling 
pathways (22–24), are differentially expressed in ECs during mor-
phogenetic differentiation on Matrigel. By employing biochemi-
cal and Tg analysis, we demonstrate that DKK1 and DKK2 play 
opposite functions in regulating angiogenesis. Importantly, DKK2 
was found to significantly improve tissue repair with functional 
neovascularization in ischemic disease models. Furthermore, this 
study provides what we believe to be novel mechanistic insights 
regarding DKK2 in stimulating angiogenic sprouting.
Results
Reciprocal expression of DKK1 and DKK2 during endothelial morphogenesis. 
To identify factors potentially acting at the sprouting front, we 
employed Affymetrix oligonucleotide arrays (GEO GSE27160) 
to isolate genes that reversibly change their expression during in 
vitro proliferation and morphogenesis of ECs. Interestingly, we 
detected reciprocal change in the expression of Dickkopf fam-
ily members DKK1 and DKK2. DKK1 was rapidly downregulated 
upon induction of morphogenesis on 2D Matrigel, whereas DKK2 
was upregulated during this process (Figure 1A). These changes 
in expression were reversible (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI42556DS1) and transcriptionally (Figure 1B) controlled during 
morphogenesis on Matrigel and proliferation on gelatin.
We further investigated the regulation of DKK1 and DKK2 gene 
expression. None of the angiogenic factors tested nor hypoxia had 
an effect on DKK1 and DKK2 expression (Supplemental Figure 2, 
A and B). However, DKK2 was sufficiently induced by EC recogni-
tion of laminin, a major component of Matrigel, and did not require 
morphological changes in ECs (Supplemental Figure 2, C–E). 
In contrast, downregulation of DKK1 was correlated with the induc-
tion of morphological changes in ECs (Supplemental Figure 2, 
Figure 1
DKK1 and DKK2 reciprocally expressed during endothelial morphogenesis distinctively regulate angiogenesis in vitro. (A) mRNA and protein 
levels of DKK1 and DKK2 at the same time points (0.5, 8, and 12 hours) during morphogenesis in Matrigel were measured by RT-PCR (left) 
and Western blotting (right). (B) Human DKK1 or DKK2 promoter activities were measured by luciferase reporter assay. HUVECs cultured on 
gelatin-coated plates were transfected and transferred to gelatin-coated plates (gelatin) or Matrigel-coated plates (morphogenesis) 6 hours later. 
Luciferase reporter activity was measured 16 hours later. Data represent mean ± SD. (C) HUVECs stably expressing eGFP plus control (CTL) 
shRNA, eGFP plus DKK1 shRNA, or DKK1 plus control shRNA were established with lentivirus. Stable transfectants were plated on Matrigel-
coated plates at a density of 1.5 × 105 cells/well and incubated for 18 hours. Capillary-like networks, which completely differentiated into tube-like 
structure, were quantified with Image-Pro Plus software. (D) Proliferative indices of HUVECs transfected with eGFP or DKK1 were assessed 
by [3H]-thymidine incorporation assay. (E) HUVECs stably expressing eGFP, DKK2, control shRNA, or DKK2 shRNA. Morphogenesis of the 
transfectants on Matrigel was analyzed as described in C. (F) Proliferative indices of HUVECs transfected with eGFP or DKK2 were accessed 
as described in D. Data represent mean ± SD. **P < 0.01; ***P < 0.001.
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F and G) and was not significantly affected by the recognition of 
specific ECM components (Supplemental Figure 2C).
Distinct roles of DKK1 and DKK2 during in vitro angiogenesis. We next 
determined the roles of DKK1 and DKK2 in angiogenesis in vitro. 
Sustained expression of DKK1 during morphogenesis or treatment 
with recombinant DKK1 protein sup-
pressed the formation of EC tube-like 
structures on 2D Matrigel (Figure 1C 
and Supplemental Figures 3 and 5). 
In contrast, overexpression of DKK2 
or treatment with recombinant DKK2 
protein enhanced the integrity of EC 
tube-like structures, while knockdown 
of DKK2 during morphogenesis inhib-
ited it (Figure 1E and Supplemental 
Figures 4 and 5). In addition, DKK2 
treatment of HUVEC-coated beads 
caused more sprouts of HUVECs com-
pared with controls on fibrin bead assay 
(Supplemental Figure 6). Interestingly, 
EC proliferation on gelatin was also 
significantly inhibited by DKK1 overex-
pression and increased by DKK1 shRNA 
transfection (Figure 1D and Supple-
mental Figure 7). Overexpression of 
DKK2 had no significant effect on EC 
proliferation on gelatin (Figure 1F). 
These results suggest that DKK1 and 
DKK2 perform opposite functions dur-
ing angiogenesis in vitro.
DKK2 is a proangiogenic factor in vivo. 
To evaluate the effects of DKK1 and 
DKK2 on angiogenesis in vivo, we 
employed the Matrigel implant assay 
in mice. DKK2- or VEGF-containing 
Matrigel plugs were red in color, imply-
ing neovascularization (Supplemental 
Figure 8). The color of Matrigel plugs 
cotreated with VEGF and DKK1 was 
similar to that of control-treated plugs 
(Supplemental Figure 8). Quantifica-
tion of hemoglobin and CD31 staining 
of Matrigel plugs consistently indicat-
ed that DKK2 significantly increases 
angiogenesis compared with controls, 
while DKK1 suppresses VEGF-induced 
angiogenesis (Figure 2, A and B).
We further examined the structural 
characteristics of DKK2-induced blood 
vessels in a mouse cornea pocket assay. 
As previously demonstrated (25), the 
growth of VEGF-induced blood ves-
sels was relatively fast, but their struc-
ture appeared to be disorganized and 
leaky (Figure 2C). In contrast, DKK2 
induced well-organized vascular net-
works with distinct vascular tree-like 
structures (Figure 2C). In addition, 
Evans blue administration demon-
strated that DKK2-induced vessels are 
less leaky than VEGF-induced vessels (Figure 2D). Compared 
with VEGF-stimulated capillaries, DKK2-induced vessels con-
sistently showed more coverage of ECs by pericytes and SMCs, 
which play an important role in vessel maturity and stability 
(Figure 2, E and F, and Supplemental Figure 9).
Figure 2
DKK2 protein induces angiogenesis in vivo. (A and B) Matrigel plugs treated with VEGF (200 ng) 
and DKK2 (1 μg) were excised from mice 5 days after injection (n = 5 per group). Scale bars: 100 μm. 
CD31 staining (A) and quantification of hemoglobin concentrations in a Matrigel plug (B). White 
arrows indicate CD31-stained vessels. (C–F) Corneal angiogenic responses induced by VEGF-
containing (200 ng) or DKK2-containing (1 μg) micropellets. Scale bars: 500 μm. Asterisks indi-
cate micropellet inserted (C). 5 days after pellet implantation, Evans blue was injected i.v. After 
30 minutes, each mouse eye was photographed. Scale bars: 200 μm (D). CD31 and NG-2 staining 
of cryosections of the eye (E). Scale bars: 100 μm. Green, CD31 positive; red, NG-2 positive; blue, 
DAPI. Pericyte coverage calculated as a ratio of the NG-2 to CD31 staining area (F). Data represent 
mean ± SD. ***P < 0.001.
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Figure 3
DKK2 Tg mice exhibit increased vessel formation in the retina. (A–F) Isolectin B4 staining of whole-mounted P4 retinas of WT or DKK2 Tg 
mice (A and D). White broken lines indicate the range of vessel extension (A). Scale bars: 500 μm. White dots indicate filopodia extended 
from tip cells (D). Scale bars: 100 μm. Quantification of vessel densities (B), sprouting length (C), tip cell number (E), and filopodia (F). (G–I) 
Isolectin B4 staining of whole-mounted P12 retinas (G). Scale bars: 100 μm. Quantification of vessel density in the ganglion (first) (H) and the 
outer nuclear (third) cell layer (I). (J–M) Aortic segments were harvested from WT and DKK2 Tg mice (n = 7 per group). (J) Endothelial sprouts 
forming branching cords from the margins of aortic segments were photographed with a phase microscope. Scale bars: 200 μm. (L) Dynamic 
movement of endothelial sprouts from the margins of aortic segments was captured as real-time video (see Supplemental Video 1). Scale bars: 
40 μm. Arrows indicate filopodia. Sprouting scores (K) and quantification of tip cell numbers (M). Sprouting scores were scored from 0 (least 
positive) to 5 (most positive). Data represent mean ± SD. *P < 0.05; ***P < 0.001. Box indicates 25%~75% value and whisker indicates media 
value in box plot (B, C, E, F, H, and I).
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Enhanced angiogenic sprouting and filopodial dynamics in DKK2 Tg 
mice. To further examine the angiogenic function of DKK2 in vivo, 
we generated Tg mice that express mDKK2 under the control of 
the EC-specific Tie2 promoter/enhancer (Supplemental Figure 10). 
In the 3 Tg mouse lines generated, we could not detect significant 
developmental abnormalities at the embryonic stage or in adults. 
However, DKK2 Tg embryos generally showed slightly increased 
capillary density at E9.5 and beyond compared with WT litter-
mates (data not shown). Since the growth rate and patterning of 
retinal blood vessels during early development are well character-
ized, we analyzed the retinal phenotype in DKK2 Tg mice. At P4, 
DKK2 Tg mice displayed increased vascular density and sprout-
ing length in retinal vasculature compared with WT littermates 
(Figure 3, A–C). The number of tip cells and filopodia were also 
consistently increased in DKK2 Tg mice (Figure 3, D–F). Ki-67 
staining also showed increased endothelial cell proliferation in 
DKK2 Tg retinas compared with WT littermates (Supplemental 
Figure 11). The discrepancy between previous in vitro results and 
current in vivo results may be due to the difference between in 
vitro culture and in vivo growth conditions. For pericyte recruit-
ment, DKK2 Tg mice did not appear to differ from WT littermates 
(Supplemental Figure 11). In P12 retinas, the vascular density, 
internal filopodia, and branching of the ganglion layer (first layer) 
as well as the vascular plexus in the deeper layer (third layer) were 
markedly increased in DKK2 Tg mice (Figure 3, G–I, and Supple-
mental Figure 12). Further, the increase in retinal vascular den-
sity was maintained up to 10 weeks after birth (Supplemental 
Figure 13). In an ex vivo aortic ring assay, the average length and 
branch number of endothelial sprouts were consistently increased 
in DKK2 Tg aortas compared with those from WT littermates 
(Figure 3, J and K, and Supplemental Figure 14). In time-lapse 
video microscopy recorded over 9 hours, DKK2 Tg aortas showed 
highly dynamic filopodial protrusion of tip cells (Figure 3, L and M, 
and Supplemental Video 1).
DKK2 promotes new vessel formation in both hind limb ischemia and 
myocardial infarction animal models. We next examined the effect of 
local injection of DKK2 protein on therapeutic neovasculariza-
tion in a murine model of hind limb ischemia. Hind limb isch-
emia was induced by ligation and excision of the right femoral 
artery and vein, resulting in a severe vascular perfusion defect 
(26). Intramuscular injection of DKK2 resulted in a significant 
reduction in necrosis compared with ischemic mice treated 
with PBS (Figure 4, A and B). Indocyanine green (ICG) imag-
ing revealed that blood perfusion was significantly improved 
at 3 days after surgery in mice injected with DKK2 compared 
with PBS-injected mice (Figure 4, A and B), consistent with the 
hypothesis that the reduced necrosis was due to improved neo-
vascularization in the ischemic limb.
We further assessed the therapeutic effect of DKK2 in a rat 
model of myocardial infarction (MI). One week after MI induction 
and DKK2 protein injection, the size of the LV infarct was evalu-
ated in the DKK2 and control (sham) groups. Injection of DKK2 
protein significantly decreased the infarct size and the degree of 
fibrosis in the infarct zone compared with sham (Figure 4, C–F). 
The mean microvessel count per field in the infarcted heart was 
also higher (Figure 4, G and H), and the incidence of TUNEL-posi-
tive myocardial cells was significantly reduced in the DKK2 group 
compared with sham (Figure 4, I and J).
Changes in cardiac function in DKK2 protein–treated MI ani-
mals were measured with transthoracic echocardiography. Echo-
cardiography data (Figure 4K, Supplemental Figure 15, and 
Supplemental Table 1) showed that DKK2 increased both LV 
fractional shortening (FS) and LV ejection fraction (EF) compared 
with sham. Injection of DKK2 or VEGF showed further improve-
ment in systolic performance and cardiac dimensions compared 
with sham animals. However, cardiac dimensions including LV end 
diastolic diameter (LVEDD) and LV end systolic diameter (LVESD) 
were smaller in the DKK2-treated group than in the VEGF-treated 
group (Supplemental Figure 15 and Supplemental Table 1). The 
DKK2 group had a higher increase in systolic performance (16.27% 
increment in percentage of FS and 20.5% increment in percentage 
of EF) than the VEGF group (Figure 4K, Supplemental Figure 15, 
and Supplemental Table 1).
DKK2-induced filopodial extrusion of ECs requires Cdc42 activation. We 
next scrutinized the mechanism of action of DKK2 in the vascula-
ture. Previous studies showed that tip cell filopodial extension in 
the developing retina depends on astrocyte-derived VEGF-A acting 
directly on tip cells (7, 8). However, glial fibrillary acidic protein 
(GFAP) and VEGF-A mRNA levels, as well as the relative levels of 
VEGF-A splice isoforms, remained unchanged in DKK2 Tg mice 
compared with WT mice (Supplemental Figure 16), suggesting a 
direct action for DKK2 in ECs.
The tips of the sprouts are composed of highly migratory cells 
with numerous filopodia- and lamellipodia-like processes, which 
are conferred by the action of small GTPases, such as Cdc42 (27). 
Therefore, we hypothesized that DKK2 may stimulate tip cell 
filopodial extension through regulating the activation of Cdc42. 
In HUVECs cultured on gelatin, overexpression of DKK2 but 
not DKK1 induced Cdc42 activation (Figure 5A). Consistently, 
both overexpression of DKK2 and treatment with DKK2 protein 
induced Cdc42 activation in retinal endothelial cells (RECs) (Sup-
Figure 4
DKK2 promotes angiogenesis and improves tissue recovery in animal 
models of hind limb ischemia and MI. (A and B) Intramuscular injec-
tion of DKK2 increased blood perfusion and reduced the probability 
of necrosis in the ischemic hind limb in mice. Tissue perfusion rate 
(%/min) was defined as the fraction of blood exchanged per minute in 
the vascular volume by time-series analysis of indocyanine green dye. 
Blood perfusion rate of the hind limb was measured at postoperative 
day 0 (POD 0). Correlation between regional perfusion rates of the 
ischemic hind limbs at POD 0 and limb necrosis levels at POD 3 was 
determined. The x axis shows the regional perfusion rate of the isch-
emic hind limbs (poor perfusion rate: 0%~30%/min; moderate perfusion 
rate: 30%~100%/min; good perfusion rate: 100 < %/min). Normal hind 
limbs typically demonstrate a perfusion rate above 400%/min. (C–J) 
Increase of myocardial repair after DKK2 injection. Myocardial injection 
of DKK2 decreased the LV infarct size as assessed by TTC staining 
at 1 week after MI (C and D). Representative images taken from a 
Masson’s trichrome–stained section (muscle is stained red, collagen 
is stained blue) (E and F). Microvessel staining with CD31 (G) and the 
TUNEL assay (I) on cardiac muscle tissues. Scale bars: 50 μm. Quan-
titative analysis of microvessel density and the TUNEL assay (H and 
J). Area with yellow broken lines (C) indicates the infarct region. Red 
arrows (G and I) indicate microvessels and apoptotic cells, respec-
tively. (K) Effective improvement of cardiac function by DKK2 injection. 
Cardiac functions were measured with 2D conventional parameters: 
FS and LVEF at 3 weeks after injection of DKK2 into MI rats. FS (%) = 
([LVEDD – LVESD]/LVEDD) × 100 (%). LVEDV = 7.0 × LVEDD3/(2.4 
+ LVEDD), LVESV = 7.0 × LVESD3/(2.4 + LVESD), and LVEF (%) = 
(LVEDV – LVESV)/LVEDV × 100. *P < 0.05; **P < 0.01; ***P < 0.001. 
S; Sham, V; VEGF, D2; DKK2. Data represent mean ± SD.
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plemental Figure 17). During HUVEC morphogenesis, Cdc42 was 
spontaneously activated in HUVECs plated on Matrigel and its 
activation was slightly potentiated in DKK2-expressing HUVECs, 
but significantly reduced in DKK1-expressing cells (Figure 5B 
and Supplemental Figure 18). In addition, HUVEC and REC filo-
podial protrusion was significantly increased by treatment with 
DKK2 protein at 2 hours compared with controls, and a domi-
nant negative form of Cdc42 blocked DKK2-induced filopodial 
extensions of HUVECs (Figure 5, C and D, and Supplemental 
Figures 17 and 19). These results suggest that DKK2 may pro-
mote angiogenesis, at least in part, by endowing the dynamics 
of tip cell structures, which require Cdc42 activation and filopo-
dial protrusion. To identify potential supporting mechanisms of 
DKK2-mediated Cdc42 activation in ECs, we determined whether 
the WNT/Frizzled complex or LRP5/6 is involved in the signaling 
events induced by DKK2. Treatment with soluble Frizzled-relat-
ed protein (sFRP), a decoy antagonist of WNT, did not inhibit 
DKK2-mediated Cdc42 activation (Figure 5E).
Interestingly, knockdown experiments of LRP5 and LRP6 
revealed that LRP6, but not LRP5, was critically involved in DKK2-
mediated Cdc42 activation, although both LRPs are expressed in 
ECs (Figure 6A and Supplemental Figure 20, A–C). Consistently, 
siRNA specific to LRP6 completely blocked DKK2-induced EC 
morphogenesis, whereas siRNA against LRP5 had no significant 
effect (Figure 6, B and C, and Supplemental Figure 15, D and E). 
LRP6 expression was also specifically detected in retinal ECs (Sup-
plemental Figure 21). These results suggest that DKK2 activates 
the Cdc42 signaling pathway via LRP6 and independent of WNT/
Frizzled signaling.
It has recently been reported that adenomatous polyposis coli 
(APC) stimulates the guanine nucleotide exchange factor (GEF) activ-
ity of APC-stimulated exchange factor 2 (Asef2), a guanine-nucleo-
tide exchange factor specific for Cdc42 (28). Since APC is one of the 
components working downstream of LRP6, we hypothesized that 
DKK2 stimulation of LRP6 might induce APC/Asef2 complex for-
mation, resulting in Cdc42 activation. Indeed, APC and Asef2 inter-
Figure 5
DKK2 increases f i lopo-
dial protrusions in a Cdc42-
dependent manner. (A) 
HUVECs stably expressing 
eGFP, DKK1, or DKK2 were 
analyzed for Cdc42 activities. 
(B) Stable transfectants were 
cultured on Matrigel-coated 
plate (morphogenesis) for 
2 hours and Cdc42 activi-
ties were measured. (C and 
D) HUVECs were transiently 
transfected with expression 
plasmids encoding eGFP 
control or eGFP dominant 
negative mutant of Cdc42 
(Cdc42 N17). After 24 hours, 
these cells were plated on 
Matrigel-coated plates and 
incubated with PBS or DKK2 
(1.5 μg/ml) for 2 hours. Then 
microphotographs were taken 
(C) and filopodia number was 
quantified (D). Arrowheads 
indicate filopodial extension. 
Data represent mean ± SD. 
**P < 0.01. Scale bars: 20 μm. 
(E) HUVECs stably express-
ing eGFP or DKK2 were incu-
bated with sFRP (200 ng/ml) 
for 24 hours and Cdc42 activ-
ity was measured.
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action was prominently increased in ECs expressing DKK2 and was 
blocked by LRP6 siRNA (Figure 6, D and E). Moreover, knockdown 
of APC or Asef2 inhibited the Cdc42 activation and EC morphogen-
esis induced by DKK2 (Figure 6, F–H, and Supplemental Figure 22). 
Taken together, these results indicate that the angiogenic action of 
DKK2 may be mediated through its cognate receptor LRP6 in ECs 
and that at least the APC/Asef2 complex lies downstream of LRP6, 
leading to Cdc42 activation and stimulation of tip cell dynamics.
Discussion
In this study, we propose different biological roles of DKK1 and 
DKK2 in regulating angiogenesis. Expression of DKK1 and DKK2 
was reciprocally and specifically regulated depending on the sta-
tus of ECs, such as proliferation and morphogenetic differentia-
tion. DKK2 promoted angiogenesis, whereas DKK1 suppressed it. 
DKK1 and DKK2 have similar primary structures and were origi-
nally identified as soluble WNT antagonists (29). These proteins 
regulate various biological functions through inhibition of the 
WNT signaling pathway (22–24). Interestingly, DKK2 is also sug-
gested to work as an activator depending on cell context (29, 30). 
However, the biological function of DKK2 as an LRP5 or LRP6 
agonist in vivo and the underlying signaling mechanism remain 
to be determined. Our finding that DKK2 promotes angiogenesis 
provides a new insight into the agonist function of DKK2 in vivo.
Figure 6
DKK2-induced Cdc42 activation requires LRP6-mediated APC/Asef2 signaling. (A–C) HUVECs stably expressing eGFP or DKK2 were tran-
siently transfected with control, LRP5-specific, or LRP6-specific siRNA. After 60 hours, Cdc42 activity was measured (A). Cells were plated on 
Matrigel-coated plates at a density of 1.5 × 105 cells/well and incubated for 18 hours. Microphotographs were taken and capillary-like networks 
were quantified with Image-Pro Plus software (B and C). (D) Coimmunoprecipitation of APC with Asef2. Lysates were prepared from cells 
overexpressing eGFP or DKK2, immunoprecipitated with anti-APC antibody, and probed with anti-Asef2 or anti-APC antibodies. (E) eGFP- or 
DKK2-expressing cells were transiently transfected with control or LRP6-specific siRNA. After 60 hours, cell lysates were subjected to coim-
munoprecipitation. (F–H) eGFP- or DKK2-expressing cells were transiently transfected with control, APC-specific, or Asef2-specific siRNA. After 
60 hours, Cdc42 activity was measured (F). The cells were plated on Matrigel-coated plates at a density of 1.5 × 105 cells/well and incubated for 
18 hours. Capillary-like networks were quantified with Image-Pro Plus software (G and H). Data represent mean ± SD. ***P < 0.001.
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Our data suggest that the angiogenic activity of DKK2 is cor-
related with activation of EC dynamics. The vascular-specific 
DKK2 Tg mice exhibited significantly increased vessel branch-
ing, EC density, and proliferation, with significantly enhanced 
numbers of tip cells and filopodia at the vascular front of the 
retina (Figure 3). Interestingly, these retinal vascular phenotypes 
of DKK2 Tg mice were comparable to those of Jag1 Tg mice as 
described previously (16). Since our study is based on the gain 
of function, it is limited to arguing whether DKK2 is involved 
in tip cell and stalk cell specification as Jag1 is. However, it is 
most likely that the angiogenic sprouting and vascular pattern-
ing governed by DKK2 might be correlated with its stimulatory 
function in tip cell dynamics, as clearly indicated in aortic ring 
imaging (Figure 3, J–M, and Supplemental Video 1). Our data 
showed that DKK2 is rapidly induced by EC recognition of lami-
nins, major components of the basement membrane. Notably, 
it has been shown that laminins were produced by stalk cells 
and tip cells during sprouting angiogenesis (31) and that lam-
inin-1 induces expression of Jag1 in ECs (32). We also observed 
that both Jag1 and DKK2 are induced in a similar way during 
morphogenesis of HUVECs on Matrigel (data not shown). Thus, 
the expression pattern and Tg phenotypes point to a potential 
relationship between Jag1 and DKK2 in sprouting angiogenesis. 
Recent in silico analysis suggested that DKK2 is a Notch signal-
ing target in intestinal stem cells (33). However, Notch-response 
elements were detected in the promoter region of DKK2 of 
human, chimpanzee, and rat, but not in cow and mouse (33). 
Thus, it remains unclear whether angiogenic action of DKK2 is 
functionally correlated with Notch signaling.
This study further provides insight into the mechanism by 
which DKK2 promotes sprouting angiogenesis. Filopodia extend-
ing from tip cells lead the angiogenic sprout by sensing guidance 
cues and migrating along a specific path in response (7). Previous 
studies have shown that Rho GTPases represent an important class 
of molecules involved in vascular morphogenesis (34, 35). DKK2, 
but not DKK1, consistently induced Cdc42 activation in ECs. 
Although cultured ECs expressed both LRP5 and LRP6, which are 
potential signaling receptors for DKK2, depletion of LRP6, but not 
LRP5, resulted in a significant reduction in DKK2-induced Cdc42 
activation and EC morphogenesis. LRP5 and LRP6 share 73% iden-
tity in protein sequences but the ligand-binding repeats show only 
50% similarity (36), which suggests that they may not bind ligands 
with similar affinity. Indeed, it has been shown that LRP6 works 
differently from LRP5 in the WNT signaling pathway. Overexpres-
sion of LRP6, but not LRP5, induces axis duplication in Xenopus 
(37), and only LRP6 cooperates with several WNT-Frizzled fusion 
proteins to activate WNT-responsive promoters (38). Similarly, 
our data suggest that the response of LRP5 and LRP6 to DKK2 in 
ECs is distinct and LRP6 may act as a cognate DKK2 receptor that 
mediates Cdc42 activation and angiogenic sprouting.
We further asked how the association of LRP6 with DKK2 
activates Cdc42. APC is known to be involved in WNT signaling 
downstream of LRP6 through its binding to β-catenin (39). Recent 
studies have uncovered an additional function for APC, in which it 
activates Cdc42 via direct binding to Asef2 (28, 40). Interestingly, 
APC/Asef2 complex formation was enhanced by DKK2, and the 
reduction of APC or Asef2 expression inhibited DKK2-induced 
Cdc42 activation and EC morphogenesis, suggesting functional 
significance of the APC/Asef2 system in linking DKK2/LRP6 to 
Cdc42 activation in ECs. Some WNT members are known to acti-
vate Cdc42 via noncanonical pathways, promoting cell polarity 
(41). However, treatment with sFRP, a decoy antagonist of WNT, 
did not inhibit DKK2-induced Cdc42 activation (Figure 5E) and 
DKK2 treatment did not increase β-catenin–mediated transcrip-
tion levels (Supplemental Figure 23), suggesting that DKK2 may 
activate Cdc42 independent of the WNT pathway.
Norrin/LRP5/Fzd4 signaling is well known in regulating reti-
nal angiogenesis. EC-specific knockout mice of Norrin or Fzd4 
showed reduced retina vessel growth and endothelial-mural cell 
interaction (42). However, blocking of Norrin/LRP5/Fzd4 signal-
ing in vitro by Fzd4 CRD IgG did not interrupt Cdc42 activation 
by DKK2. In addition, Cdc42 activation was not affected by Norrin 
treatment (Supplemental Figure 24). In summary, CDC42 activa-
tion by the DKK2/LRP6 pathway does not seem to be affected by 
Norrin/LRP5/Fzd4 signaling.
Our data also demonstrate an inhibitory function of DKK1 in 
angiogenesis with 2 possible mechanisms. First, unlike the WNT-
independent mechanism of DKK2 in vascular morphogenesis, 
DKK1 appears to directly affect WNT signaling in ECs. Previous 
studies have demonstrated roles for the WNT signaling pathway 
in angiogenesis and vascular stability (18, 43). Signals transmit-
ted from the Frizzled family of receptors upon binding of its 
ligands, WNT and Norrin, influence angiogenic processes such as 
EC proliferation and migration (17). Moreover, mice deficient in 
Lef1 and Ctnnb1, both of which control transcription of target 
genes of the canonical WNT signaling pathway, displayed signifi-
cant reduction in vascular density in retinas (44). Our data show 
that DKK1 inhibits WNT-responsive promoter activity and pro-
liferation of ECs (Figure 1D and Supplemental Figure 25), and 
endothelium-specific overexpression of DKK1 in mice results in 
delayed peripheral vascularization and reduced vascular density in 
retinas (Supplemental Figure 26). Alternatively, DKK1 may coun-
teract DKK2 action through competitive binding to LRP6. This 
mechanism is supported by our data showing that upregulation 
of DKK1 antagonizes DKK2-induced angiogenic sprouting and 
Cdc42 activation (Supplemental Figure 26).
Although knockout of DKK1 and DKK2 showed unique pheno-
types in head formation and osteoblast differentiation (45, 46), 
respectively, no obvious vascular phenotype in mutant mice has 
been reported so far. This may be due to the compensation for 
DKK1 and DKK2 deficiency by other members of DKK family 
(47) or other regulatory factors during normal vascular devel-
opment. And also, considering the complexity and diversity of 
blood vessels in different organs and pathological states, care-
ful reexamination of vascular phenotypes in DKK-deficient mice 
may be valuable for further understanding the precise roles of 
DKKs in the vasculature.
The feature of DKK2-induced vessels, which were structurally 
organized and well covered by pericytes and SMCs, was differ-
ent from those induced by VEGF as shown by the corneal assay. 
DKK2 also provided profound therapeutic effects in 2 ischemic 
disease models mentioned above. Although the discovery of sev-
eral angiogenic factors has led to the development of therapeutic 
strategies for ischemic diseases, the success of therapeutic angio-
genesis in clinical trials has been limited due to insufficient effi-
cacy and pronounced adverse effects (48–51). Given that DKK2 
is a relatively small and soluble ligand, our finding that DKK2 
alone can induce new and functional vessel formation in vivo may 
provide a novel strategy for developing therapeutic strategies to 
treat ischemic vascular diseases.
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Methods
Cell culture. HUVECs were isolated from human umbilical cord veins by col-
lagenase treatment, as described previously (52), and used from passages 
2–4. HUVECs were cultured in EC basal medium (EBM) or EC growth 
medium (EGM, Clonetics) supplemented with 3% FBS.
In vitro morphogenesis on 2D Matrigel and oligonucleotide microarrays. In vitro 
morphogenesis was assayed as previously described (53). Briefly, 800 μl 
of growth factor–reduced Matrigel (BD Biosciences) was transferred to a 
60-mm tissue culture well and polymerized for 30 minutes at 37°C. 
HUVECs were plated onto the layer of Matrigel at 1 × 106 cells/plate and 
cultured for 0.5, 8, or 18 hours. At each time point, total RNA was isolated 
and hybridized to the HG-U133A 2.0 microarray (54675 human genes; 
Affymetrix). The standard protocol used for sample preparation and 
microarray processing is available from Affymetrix. Full data sets are avail-
able online (Gene expression analysis during morphogenesis of Human 
umbilical vein endothelial cells; GEO GSE27160).
EC proliferation assay. HUVECs were seeded at 2 × 104 cells/well in gel-
atin-coated 24-well plates. After 48 or 72 hours, cells were washed twice 
with M199 and incubated for 6 hours in M199 containing 0.5 μCi/ml of 
[3H]thymidine (Amersham). High–molecular weight DNAs were precipi-
tated using 10% trichloroacetic acid at 4°C for 30 minutes. After 2 washes 
with ice-cold H2O, 3H-radioactivity was solubilized in 0.2 N NaOH/0.1% 
SDS and determined by liquid scintillation counter.
In vivo Matrigel plug assay. The Matrigel plug assay was performed as previ-
ously described. Briefly, 7-week-old C57BL/6 mice (Orient Co.) were injected 
subcutaneously with 0.6 ml of Matrigel containing the indicated amount of 
DKK2, DKK1, VEGF+DKK1, and 10 units of heparin. The injected Matrigel 
rapidly formed a single, solid gel plug. After 5 days, the skin of the mouse 
was easily pulled back to expose the Matrigel plug, which remained intact. 
Hemoglobin was measured by the Drabkin method with Drabkin Reagent 
Kit 525 (Sigma-Aldrich) to quantify blood vessel formation. The concentra-
tion of hemoglobin was calculated from a known amount of hemoglobin 
assayed in parallel. To identify infiltrating ECs, immunohistochemistry was 
performed with anti–CD-31 antibody (BD Biosciences).
Mouse corneal pocket assay. Eight-week-old C57BL/6 mice were anesthe-
tized with zoletil 50 (15 mg/kg) and lumpun (5 mg/kg). After 10 minutes, 
alcaine was dropped into the eye. With a von Graefe cataract knife, a micro-
pocket was made in the cornea. Micropellets (0.35 × 0.35 mm) of sucrose 
octasulfate-aluminum complex (s0652; Sigma-Aldrich) coated with poly-
2-hydroxyethyl methacrylate (p3932; Sigma-Aldrich) containing 200 ng of 
VEGF (K0921632; KOMABIOTECH) and 1 μg of DKK2 were implanted 
into the corneal micropocket. The pellet was positioned 0.6–0.8 mm from 
the corneal limbus. Tardomyocel-L ointment was applied to the eye after 
implantation. Eyes were examined with a microscope 7 days after implan-
tation. Cryosections were stained with anti-CD31 (BD Pharmingen) and 
anti-NG2 (Millipore) antibodies.
Aortic ring assay. Aortas were harvested from 6- to 8-week-old C57BL/6 
WT and DKK2 Tg mice. Plates (48-well) were coated with 100 μl Matrigel, 
and after it had gelled, the rings were placed in the wells and sealed in place 
with an overlay of 40 μl Matrigel. EGM was added to the wells in a final vol-
ume of 200 μl of human endothelial serum-free medium (Invitrogen). On 
day 5, cells were fixed and stained with isolectin B4. The assays were scored, 
double-blinded, from 0 (least positive) to 5 (most positive). Each data point 
was assayed 6 times. Endothelial sprouts were time-lapse imaged on an 
Olympus IX81-ZDC inverted fluorescence microscope (Olympus).
Analysis of mouse retinal vasculature. The vascular pattern of dissected 
mouse retina was analyzed using a modification of a method previously 
reported (7). Mice were sacrificed by ketamine injection and eyes were 
enucleated in PBS. The eyes were fixed in 4% PFA-PBS (pH 7.4) for 1 hour 
at 4°C. Retinas were dissected as described (54), postfixed in 70% ethanol 
overnight at 4°C, washed with PBS, and permeabilized with PBS contain-
ing 1% Triton X-100 for 1 hour. Retinas were then incubated in blocking 
solution for 4 hours at 37°C, followed by overnight incubation in Alexa 
Fluor 488–conjugated Isolectin GS-IB4 solution (Molecular Probes) at 4°C. 
After 5 washes in PBS containing 1% Triton X-100, the retinas were flat 
mounted on slides using fluorescent mounting medium. Flat-mounted 
retinas were analyzed by fluorescence microscopy using an Olympus IX81-
ZDC inverted fluorescence microscope and confocal fluorescent micro-
scope (LSM 510 META; Carl Zeiss).
Cryosection immunofluorescence staining. Tissue was fixed in 4% PFA-PBS 
(pH 7.4) overnight at 4°C and rinsed with PBS at room temperature. Tissue 
was incubated in 15% sucrose solution overnight at 4°C and then trans-
ferred to 30% sucrose at 4°C until the tissue sank. All fixation, rinsing, 
and incubation were done gently. Tissue was infiltrated in OCT embed-
ding medium (Tissue Tek) for 0.5 hours at room temperature before freez-
ing. Tissue was transferred to an embedding mold, which was filled with 
OCT. The mold was cooled with liquid nitrogen. After the material had 
frozen, tissue was wrapped in aluminum foil and stored at –70°C. Sections 
(8- to 50-μm thick) were cut at –20°C, and slides were stored at –70°C 
until needed. Sections were prefixed in acetone for 0.5 hours at –70°C and 
then dried briefly until the acetone was removed. OCT was removed with 
water. Sections were incubated in blocking solution for 4 hours at 37°C or 
overnight at 4°C, followed by overnight incubation in primary antibody at 
4°C. After 5 washes in 0.3% Triton X-100 in PBS for 15 minutes each, the 
sections were incubated in secondary antibody overnight at 4°C. Before 
washing, the sections were treated with DAPI (1 μg/ml) and washed 5 more 
times with 0.3% Triton X-100 in PBS for 15 minutes each. All antibodies 
were dissolved in antibody diluent (Dako). Sections were analyzed by fluo-
rescence microscopy using an Olympus IX81-ZDC inverted fluorescence 
microscope or a confocal microscope (LSM 510 META; Carl Zeiss).
Murine hind limb ischemia model. BalB/cAnNCriBgi-nu nude male mice were 
obtained from Charles River Japan. All mice were 7–8 weeks (15–20 g) of age 
at the time of study. Hind limb ischemia was induced by ligation and exci-
sion of the right femoral artery and vein under ketamine-xylazine anesthe-
sia. For angiogenic potential studies, mice were divided into 3 groups after 
induction of ischemia. Mice received intramuscular injection of PBS (20 μl 
with 0.9% NaCl) alone as a control, saline solution containing DKK2 (20 μl 
of 600 ng/μl), or saline solution containing VEGF (20 μl of 150 ng/μl).
NIR fluorescence imaging. We used customized optical systems for NIR 
fluorescence imaging, as previously described by Kang et al. (55). Briefly, 
this system employs a CCD digital camera (PIXIS 1024; Princeton Instru-
ments) with a custom-made 830-nm band-pass filter (Asahi Spectra USA) 
and 760-nm light-emitting diode arrays (SMC760; Marubeni America). For 
time-series ICG imaging, mice under ketamine-xylazine anesthesia were 
injected with an i.v. bolus of ICG (0.1 ml of 400 mM/l; Sigma-Aldrich) into 
the tail vein. ICG fluorescence images were obtained in a dark room for 
10 minutes at 1-second intervals immediately after injection. After serial 
imaging, customized computer programs were used to obtain perfusion 
maps and necrosis probabilities.
MI model and experimental procedure. MI was induced in 8-week-old 
Sprague-Dawley male rats (56). Rats were anesthetized with ketamine 
(10 mg/kg) and xylazine (5 mg/kg), and surgical occlusion of the left ante-
rior descending coronary artery was performed with a 6-0 silk suture (John-
son and Johnson). 60 minutes after occlusion, the myocardium was reper-
fused, and 3 μg of protein was injected into 3 sites from the injured region 
to the border using a Hamilton syringe (Hamilton Co.) with a 30-gauge 
needle. Throughout the operation, rats were ventilated with 95% O2 and 
5% CO2 using a Harvard ventilator. Six animals per group were used for 
morphologic analysis at 1 week after the operation. For functional studies, 
we performed echocardiography at 3 weeks. To determine infarct size, the 
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hearts were removed, perfused with 1% 2,3,5-triphenyltetrazolium chloride 
(TTC; Sigma-Aldrich) solution, pH 7.4, at 37°C for 20 minutes, and then 
fixed in 10% PBS-buffered formalin overnight at 2–8°C.
Histology and immunohistochemistry of the rat MI model. The heart was excised, 
fixed with 10% PBS-buffered formalin for 24 hours, and embedded in par-
affin. Sections (5-μm thick) were mounted on gelatin-coated glass slides 
to allow the use of different stains on sections. After deparaffinization and 
rehydration, the tissue sections were stained with Masson’s trichrome for 
analysis of fibrosis. For histological analysis, an R.T.U. VECTASTATIN 
Universal Quick Kit (Vector Laboratories) was used for paraffin sections. 
Sections were deparaffinized, rehydrated, and rinsed with PBS. Antigen 
retrieval was performed by microwaving for 10 minutes in 10 mM sodium 
citrate (pH 6.0). Sections were incubated in 3% H2O2 to quench endogenous 
peroxidase activity. Sections were blocked in 2.5% normal horse serum and 
incubated in primary antibody (CD31). Biotinylated pan-specific univer-
sal secondary antibody and streptavidin/peroxidase complex reagent were 
used for the heart sections, which were stained with antibody using a DAB 
substrate kit (Vector Laboratories). Sections were counterstained with 
1% methyl green and dehydrated in 100% N-butanol, ethanol, and xylene 
before mounting in VectaMount Medium (Vector Laboratories).
Tissue TUNEL assay. The TUNEL assay was performed according to the 
manufacturer’s instructions (Chemicon International). A positive control 
sample was prepared from a normal heart section by treating the section 
with DNase I (10 U/ml, 10 minutes at room temperature). Sections were 
pretreated with 3.0% H2O2, subjected to TdT enzyme at 37°C for 1 hour, 
and incubated in digoxigenin-conjugated nucleotide substrate at 37°C 
for 30 minutes. Nuclei exhibiting DNA fragmentation were visualized by 
adding 3,3-diaminobenzidine (DAB; Vector Laboratories) for 5 minutes. 
Finally, sections were counterstained with methyl green and analyzed with 
light microscopy. For each group, 6 sections were prepared, and 10 differ-
ent regions were observed per section (×200).
Echocardiography. Transthoracic echocardiographic studies were performed 
by an experienced cardiologist blinded to group assignments, using a GE 
Vivid Seven ultrasound machine (GE Medical System) with a 10.0-MHz 
transducer. Rats received general anesthesia and were placed in the left lat-
eral decubitus position. The echo transducer was placed on the left hemi-
thorax, and short axis views were recorded. Two-dimensional images were 
obtained at midpapillary level (56). M-mode tracing of LV contraction was 
obtained at the same level as the short-axis view. LVEDD and LVESD were 
measured with M-mode tracing. Percentage of FS was calculated using the 
following equation: ([LVEDD – LVESD]/LVEDD) × 100 (%). LV end diastolic 
volume (LVEDV) was calculated as 7.0 × LVEDD3/(2.4 + LVEDD); LV end 
systolic volume (LVESV) as 7.0 × LVESD3/(2.4 + LVESD); and LV EF as EF (%) 
= (LVEDV – LVESV)/LVEDV × 100. Two images per view were obtained, and 
each parameter was measured from 3 consecutive beats per image. Six values 
of each parameter were obtained and averaged. Echocardiograms were stored 
digitally and analyzed with EchoPAC with custom 2D strain rate imaging 
software. More than 3 images were obtained in the short axis view, and the 
parameters were measured from 3 consecutive beats in each image.
RT-PCR analysis. Total RNA was isolated from HUVECs using a TRIzol 
reagent kit. Different amounts of total RNA (0.5–5 μg) were amplified with 
RT-PCR, and the correlation between the amount of RNA used and the level 
of PCR products obtained from target mRNAs and the internal standard 
(GAPDH) mRNA was examined. Briefly, cDNA was synthesized from target 
RNA using 200 U of reverse transcriptase and 500 ng of oligo(dT) primer in 
50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM DTT, and 1 mM 
dNTPs at 42°C for 1 hour. The reaction was stopped by heating at 70°C for 
15 minutes. A total of 1 μl of the cDNA mixture was then used for enzymatic 
amplification. PCR was performed in 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 
1.5 mM MgCl2, 0.2 mM dNTPs, 2.5 U of TaqDNA polymerase (Promega), 
and 0.1 μM of each primer for target genes in a DNA thermal cycler (model 
PTC-200; MJ Research) under the following conditions: denaturation at 
94°C for 5 minutes for the first cycle and for 30 seconds starting from the 
second cycle, annealing at 55°C for 30 seconds, and extension at 72°C for 
30 seconds for 25 cycles. Final extension was at 72°C for 10 minutes.
The following primer pairs were designed for RT-PCR and synthesized 
by Bioneer Inc.: mDkk2_A, 5′-CAGAGATGGGATGTGTTGCC-3′ and 
5′-CCTGATGGAGCACTGGTTTG-3′; mDkk2_B, 5′-GATGGGTTTT-
GTTGTGCTCG-3′ and 5′-ATGTTTCAGGTTCAGGGGGA-3′; mGapdh, 
5′-CGCCACAGTTTCCCGGAGGG-3′ and 5′-CCCTCCAAAATCAAGT-
GGGG-3′; DKK1, 5′-CCTGGAGTGTAAGAGCTTTG-3′ and 5′-CCAAGA-
GATCCTTGCGTT-3′; DKK2, 5′-TAGAGATTGAGTTTGAGCCT-3′ and 
5′-AAAGGGTGGACATAAGAAA-3′; KREMEN2, 5′-CACCGACTGTGAC-
CAGAT-3′ and 5′-GAGTAGATGACGCCCTGAG-3′; LRP6, 5′-GTCCTTC-
CACTCATAGGTCA-3′ and 5′-GTGGGTAGAGGTGATGAGAA-3′; LRP5, 
5′-GGGTGGTGTCTATTTTGTGT-3′ and 5′-CCGGAATGTTTGAAGAG-
TAG-3′; APC, 5′-CAGGCAAAACAAAATGTGGG-3′ and 5′-CGCTTAG-
GACTTTGGGTTCC-3′; Asef2, 5′-TCTACTCGGGGGAGCTGACT-3′ and 
5′-CCTGCTTCCTCTGCAGTTCA-3′; GAPDH, 5′-CGCCACAGTTTCCC-
GGAGGG-3′ and 5′-CCCTCCAAAATCAAGTGGGG-3′.
Cdc42 assay. Cdc42 activity was measured with a CDC42 activation kit 
(Upstate Biotechnology) according to the manufacturer’s instructions. 
HUVECs were washed once with ice-cold PBS and lysed with lysis buf-
fer containing 25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630, 
10 mM MgCl2, 1 mM EDTA, 10% glycerol, 1 mM Na3VO4, 10 μg/ml apro-
tinin, 10 μg/ml leupeptin, and 25 mM NaF for 15 minutes at 4°C. Insoluble 
materials were removed by centrifugation. Five micrograms of PAK1-agarose 
beads, which specifically bind to active Cdc42, were added to the cell lysates 
and incubated for 1 hour at 4°C. Agarose beads were washed with lysis buf-
fer 3 times and boiled in 2× Laemmli sample buffer. Samples were resolved 
by SDS-PAGE and immunoblotted with an anti-Cdc42 antibody.
Animal studies. All mice were maintained in a laminar airflow cabinet 
under specific pathogen–free conditions. All facilities were approved by the 
AAALAC (Association of Assessment and Accreditation of Laboratory Ani-
mal Care). All animal experiments were conducted under the institutional 
guidelines established for the Animal Core Facility at Yonsei University 
College of Medicine and were approved by the IACUC, Yonsei University.
Statistics. Data are presented as mean ± SD or ± SEM. Statistical com-
parisons between groups were performed using 1-way analysis of variance 
(ANOVA) followed by Student’s t test (1-tailed).
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